[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20110780T2 - Aminoarilsulfonamidni spojevi i njihova upotreba kao ligandi 5-ht6 - Google Patents

Aminoarilsulfonamidni spojevi i njihova upotreba kao ligandi 5-ht6 Download PDF

Info

Publication number
HRP20110780T2
HRP20110780T2 HRP20110780TT HRP20110780T HRP20110780T2 HR P20110780 T2 HRP20110780 T2 HR P20110780T2 HR P20110780T T HRP20110780T T HR P20110780TT HR P20110780 T HRP20110780 T HR P20110780T HR P20110780 T2 HRP20110780 T2 HR P20110780T2
Authority
HR
Croatia
Prior art keywords
sulfonyl
diamine
dimethylethane
methylindole
phenyl
Prior art date
Application number
HRP20110780TT
Other languages
English (en)
Inventor
Venkata Satya Ramakrishna Nirogi
Sastri Kambhampati Rama
Karbhari Shinde Anil
Vishwottam Kandikere Nagaraj
Jasti Venkateswarlu
Original Assignee
Suven Life Sciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Limited filed Critical Suven Life Sciences Limited
Publication of HRP20110780T1 publication Critical patent/HRP20110780T1/hr
Publication of HRP20110780T2 publication Critical patent/HRP20110780T2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

Spoj formule (I) naznačen time što R1 predstavlja vodik, hidroksil, halogen, (C1-C3)alkil, halogen(C1-C3)alkil, (C1-C3)alkoksi, halogen(C1-C3)alkoksi, ciklo(C3-C6)alkil ili ciklo(C3-C6)alkoksi; R2 predstavlja vodik, halogen, (C1-C3)alkil, halogen(C1-C3)alkil, (C1-C3)alkoksi ili halogen(C1-C3)alkoksi, ciklo(C3-C6)alkil ili ciklo(C3-C6)alkoksi; R predstavlja vodik ili (C1-C3)alkil ili (C3-C6)cikloalkil; "n" predstavlja 0 do 4; "p" predstavlja 0 do 6; "q" predstavlja 0 do 4. Patent sadrži još 12 patentnih zahtjeva.

Claims (13)

1. Spoj formule (I) [image] naznačen time što R1 predstavlja vodik, hidroksil, halogen, (C1-C3)alkil, halogen(C1-C3)alkil, (C1-C3)alkoksi, halogen(C1-C3)alkoksi, ciklo(C3-C6)alkil ili ciklo(C3-C6)alkoksi; R2 predstavlja vodik, halogen, (C1-C3)alkil, halogen(C1-C3)alkil, (C1-C3)alkoksi ili halogen(C1-C3)alkoksi, ciklo(C3-C6)alkil ili ciklo(C3-C6)alkoksi; R predstavlja vodik ili (C1-C3)alkil ili (C3-C6)cikloalkil; "n" predstavlja 0 do 4; "p" predstavlja 0 do 6; "q" predstavlja 0 do 4.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je po mogućnosti vodik, hidroksil, halogen, (C1-C3)alkil, halogen(C1-C3)alkil, (C1-C3)alkoksi ili halogen(C1-C3)alkoksi.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R2 je po mogućnosti vodik, halogen, (C1-C3)alkil, halogen(C1-C3)alkil, (C1-C3)alkoksi, halogen(C1-C3)alkoksi, ciklo(C3-C6)alkil ili ciklo(C3-C6)alkoksi.
4. Spoj u skladu s patentnim zahtjevom 1, naznačen time što R je po mogućnosti vodik ili (C1-C3)alkil.
5. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira se iz skupine koju čine: N'-[2-Metoksi-5-(5-metoksi-3-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[5-(3-Klor-5-metoksiindolo-1-sulfonil)-2-metoksifenil]-N,N-dimetileten-1,2-diamin; N'-[5-(3-Klor-indol-1-sulfonil)-2-metoksifenil]-N,N-dimetiletan-1,2-diamin; N'-[5-(Indol-1-sulfonil)-2-metoksifenil]-N,N-dimetiletan-1,2-diamin; N'-[2-Metoksi-5-(3-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[5-(5-Metoksi-3-metilindol-1-sulfonil)-2-metilfenil]-N,N-dimetilpropan-1,3-diamin; N'-[5-(5-Metoksiindol-1-sulfonil)-2-metilfenil]-N,N-dimetiletan-1,2-diamin; N'-[5-(5-Metoksi-3-metilindol-1-sulfonil)-2-metilfenil]-N,N-dimetiletan-1,2-diamin; N'-[5-(5-Metoksiindol-1-sulfonil)-2-metilfenil]-N,N-dimetilpropan-1,3-diamin; N'-[3-(4-Klor-3-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[3-(5-Klor-3-metilindol-1-sulfonil)-2-etilfenil]-N,N-dimetiletan-1,2-diamin; N'-[2-Etil-5-(5-fluor-3-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[2-Etil-5-(5-fluorindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[2-Etil-5-(5-klorindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[2-Etil-5-(5-metoksi-3-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[3-(5-Izopropoksi-3-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[5-(5-Brom-3-metilindol-1-sulfonil)-2-klorfenil]-N,N-dimetiletan-1,2-diamin; N'-[3-(5-Etoksi-3-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[5-(5-Brom-3-metilindol-1-sulfonil)-2-etilfenil]-N,N-dimetiletan-1,2-diamin; N'-[5-(6-Klorindol-1-sulfonil)-2-metilfenil]-N,N-dimetiletan-1,2-diamin; N'-[3-(5-Bromindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[3-(5-Izopropoksiindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[3-(6-Klorindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[5-(5-Bromindol-1-sulfonil)-2-etilfenil]-N,N-dimetiletan-1,2-diamin; N'-[3-(4-Klorindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[2-Etil-5-(5-metoksiindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[3-(5-Metoksi-3-metilindol-1-sulfonil)fenil]-N,N-dimetilpropan-1,3-diamin; N'-[2-Metoksi-5-(5-klor-3-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[3-(5-Metoksi-3-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[2-Metoksi-5-(5-klor-3-metilindol-1-sulfonil)fenil]-N,N-dimetilpropan-1,3-diamin; N'-[2-Metoksi-5-(3-metilindol-1-sulfonil)fenil]-N,N-dimetilpropan-1,3-diamin; N'-[2-Metoksi-5-(5-brom-3-metilindol-1-sulfonil)fenil]-N,N-dimetilpropan-1,3-diamin; N'-[2-Metoksi-5-(5-fluor-3-metilindol-1-sulfonil)fenil]-N,N-dimetilpropan-1,3-diamin; N'-[2-Metoksi-5-(5-fluor-3-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[2-Metoksi-5-(5-metoksi-3-metilindol-1-sulfonil)fenil]-N,N-dimetilpropan-1,3-diamin; N'-[3-(5-Fluor-3-metilindol-1-sulfonil)-5-metoksifenil]-N,N-dimetiletan-1,2-diamin; N'-[3-Klor-5-(5-etil-3-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[3-(5-Fluor-3-metilindol-1-sulfonil)-5-metilfenil]-N,N-dimetiletan-1,2-diamin; N'-[4-Metoksi-3-(5-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[4-Brom-3-(5-metoksiindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; N'-[3-(5-Etil-3-metilindol-1-sulfonil)-4-metilfenil]-N,N-dimetiletan-1,2-diamin; N'-[2-Klor-3-(5-metoksi-2-metilindol-1-sulfonil)fenil]-N,N-dimetiletan-1,2-diamin; njihovi stereoizomeri i njihove farmaceutski prihvatljive soli.
6. 5. Postupak dobivanja spoja formule (I) [image] gdje R1 predstavlja vodik, hidroksil, halogen, (C1-C3)alkil, halogen(C1-C3)alkil, (C1-C3)alkoksi, halogen(C1-C3)alkoksi, ciklo(C3-C6)alkil ili ciklo(C3-C6)alkoksi; R2 predstavlja vodik, halogen, (C1-C3)alkil, halogen(C1-C3)alkil, (C1-C3)alkoksi ili halogen(C1-C3)alkoksi, ciklo(C3-C6)alkil ili ciklo(C3-C6)alkoksi; R predstavlja vodik ili (C1-C3)alkil ili (C3-C6)cikloalkil; "n" predstavlja 0 do 4; "p" predstavlja 0 do 6; "q" predstavlja 0 do 4; naznačen time što se sastoji u reakciji spoja formule (a) [image] gdje su svi supstituenti kao stoje opisano gore; s aminskim derivatima, uz upotrebu pogodne baze, u prisutnosti inertnog otapala, na temperaturi okoliša.
7. 6. Postupak u skladu s patentnim zahtjevom 6, naznačen time što se navedenu bazu bira između kalijevog karbonata i natrijevog hidroksida.
8. 7. Postupak u skladu s patentnim zahtjevom 6 i/ili 7, naznačen time što se navedeno inertno otapalo bira između diklormetana, dimetilformamida, dimetil-sulfoksida i w-ksilena.
9. 8. Farmaceutski pripravak, naznačen time što sadrži spoj formule (I) u skladu s patentnim zahtjevom 1 do 5 i farmaceutski prihvatljivu podlogu, razrjeđivač, pomoćnu tvar ili solvat.
10. 9. 10. Farmaceutski pripravak u skladu s patentnim zahtjevom 9, naznačen time stoje u obliku tablete, kapsule, praška, sirupa, otopine, injekcije ili suspenzije i primijenjuje se kao jednu dozu ili više jedinica doze.
11. 10. 11. Farmaceutski pripravak u skladu s patentnim zahtjevom 9 i/ili 10, naznačen time stoje namijenjen upotrebi u liječenju bolesti ili poremećaja središnjeg živčanog sustava povezanih s ili pod utjecajem receptora 5-HT6 i bira ih se iz skupine koju čine motorički poremećaj, anksiozni poremećaj, kognitivni poremećaj, neurodegenerativni poremećaj, Alzheimerova bolest, Huntingtonova koreja, gastrointestinalni, kognitivni poremećaj povezan sa shizofrenijom, blagi kognitivni poremećaj, poremećaji hranjenja, anksioznost, depresija, pretilost i/ili Parkinsonova bolest.
12. 11. Spoj formule (I), u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što ga se upotrebljava u proizvodnji medikamenta za liječenje ili sprječavanje bolesti ili poremećaja središnjeg živčanog sustava povezanih s ili pod utjecajem receptora 5-HT6 i bira ih se iz skupine koju čine motorički poremećaj, anksiozni poremećaj, kognitivni poremećaj, neurodegenerativni poremećaj, Alzheimerova bolest, Huntingtonova koreja, gastrointestinalni, kognitivni poremećaj povezan sa shizofrenijom, poremećaji hranjenja, anksioznost, depresija, pretilost i/ili Parkinsonova bolest.
13. 12. Sredstvo za sprječavanje ili liječenje bolesti ili poremećaja središnjeg živčanog sustava povezanih s ili pod utjecajem receptora 5-HT6 i biraju se iz skupine koju čine motorički poremećaj, anksiozni poremećaj, kognitivni poremećaj, neurodegenerativni poremećaj, Alzheimerova bolest, Huntingtonova koreja, gastrointestinalni, kognitivni poremećaj povezan sa shizofrenijom, poremećaji hranjenja, anksioznost, depresija, pretilost i/ili Parkinsonova bolest; naznačeno time što kao aktivni sastojak sadrži spoj formule (I) u skladu s bilo kojim od prethodnih patentnih zahtjeva.
HRP20110780TT 2007-10-26 2011-10-26 Aminoarilsulfonamidni spojevi i njihova upotreba kao ligandi 5-ht6 HRP20110780T2 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2433CH2007 2007-10-26
EP08776656A EP2200980B9 (en) 2007-10-26 2008-05-02 Amino arylsulfonamide compounds and their use as 5-ht6 ligands field of invention
PCT/IN2008/000281 WO2009053997A1 (en) 2007-10-26 2008-05-02 Amino arylsulfonamide compounds and their use as 5-ht6 ligands

Publications (2)

Publication Number Publication Date
HRP20110780T1 HRP20110780T1 (hr) 2011-11-30
HRP20110780T2 true HRP20110780T2 (hr) 2018-06-29

Family

ID=39769531

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20110780TT HRP20110780T2 (hr) 2007-10-26 2011-10-26 Aminoarilsulfonamidni spojevi i njihova upotreba kao ligandi 5-ht6

Country Status (21)

Country Link
US (1) US7964627B2 (hr)
EP (1) EP2200980B9 (hr)
JP (1) JP5236001B2 (hr)
KR (1) KR101268654B1 (hr)
CN (1) CN101835748B (hr)
AT (1) ATE518833T1 (hr)
AU (1) AU2008315309B2 (hr)
BR (1) BRPI0816571A2 (hr)
CA (1) CA2703157C (hr)
CY (1) CY1112181T1 (hr)
DK (1) DK2200980T3 (hr)
EA (1) EA017154B1 (hr)
ES (1) ES2370680T3 (hr)
HK (1) HK1147750A1 (hr)
HR (1) HRP20110780T2 (hr)
IL (1) IL205231A (hr)
MX (1) MX2010003765A (hr)
NZ (1) NZ585374A (hr)
SI (1) SI2200980T1 (hr)
WO (1) WO2009053997A1 (hr)
ZA (1) ZA201002165B (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102153884B (zh) * 2011-02-16 2013-06-19 连云港清泰化工有限公司 一种墨水型染料及其制备方法与用途
EP2763676B1 (en) 2011-10-03 2019-12-25 The University of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
US20130202581A1 (en) * 2012-02-02 2013-08-08 Curelon Llc Enzyme compositions and use thereof for wound healing
WO2015090233A1 (en) 2013-12-20 2015-06-25 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
HUE044011T2 (hu) * 2014-08-16 2019-09-30 Suven Life Sciences Ltd 1-[(2-bromofenil) szulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)metil]-1H-indol dimezilát monohidrát aktív metabolitja és az aktív metabolit dimezilát dihidrát sója

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
ES2244082T3 (es) 1997-07-11 2005-12-01 Smithkline Beecham Plc Derivados de sulfonamida que son antagonistas del receptor 5-ht6 y procedimiento para su preparacion.
ES2193607T3 (es) * 1998-01-16 2003-11-01 Hoffmann La Roche Derivados de benzosulfona .
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
DE69937372T2 (de) 1999-04-21 2008-06-26 Nps Allelix Corp., Mississauga Piperidin-indol derivate mit 5-ht6 affinität
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
EP1377580B1 (en) 2001-01-30 2006-09-27 Eli Lilly And Company Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor
AU2002313673B2 (en) 2001-02-08 2006-09-07 Memory Pharmaceuticals Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
BR0210929A (pt) 2001-06-07 2004-06-08 Hoffmann La Roche Derivados de indol com afinidade para o receptor 5-ht6
US20050255529A1 (en) 2002-02-01 2005-11-17 Stefan Golz Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
JP2005522432A (ja) 2002-02-05 2005-07-28 グラクソ　グループ　リミテッド ニューロン成長の促進方法
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
WO2004035047A1 (en) * 2002-10-18 2004-04-29 F. Hoffmann-La Roche Ag 4-piperazinyl benzenesulfonyl indoles with 5-ht6 receptor affinity
AU2003292508A1 (en) * 2002-11-28 2004-06-18 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
ES2310243T3 (es) 2002-11-28 2009-01-01 Suven Life Sciences Limited Indoles n-aril-3-sulfonil sustituidos que tienen afinidad por receptores de serotonina, proceso para su preparacion y composicion farmaceutica que los contiene.
NZ540842A (en) * 2002-11-28 2008-05-30 Suven Life Sciences Ltd N-arylsulfonyl-3-aminoalkoxyindoles
DK1581538T3 (da) 2002-12-18 2007-06-25 Suven Life Sciences Ltd Tetracykliske 3-substituerede indoler med serotoninreceptoraffinitet
CN101258144B (zh) * 2005-08-12 2012-05-30 苏文生命科学有限公司 作为功能性5-ht6配体的氨基芳基磺酰胺衍生物

Also Published As

Publication number Publication date
HRP20110780T1 (hr) 2011-11-30
HK1147750A1 (en) 2011-08-19
ATE518833T1 (de) 2011-08-15
DK2200980T3 (da) 2011-11-21
ZA201002165B (en) 2011-05-25
EA201070527A1 (ru) 2010-10-29
ES2370680T3 (es) 2011-12-21
JP5236001B2 (ja) 2013-07-17
NZ585374A (en) 2011-09-30
EP2200980B9 (en) 2011-12-28
CN101835748A (zh) 2010-09-15
CY1112181T1 (el) 2015-12-09
EA017154B1 (ru) 2012-10-30
CN101835748B (zh) 2012-11-14
EP2200980B1 (en) 2011-08-03
BRPI0816571A2 (pt) 2015-12-22
WO2009053997A1 (en) 2009-04-30
EP2200980A1 (en) 2010-06-30
MX2010003765A (es) 2010-04-30
US20100216861A1 (en) 2010-08-26
US7964627B2 (en) 2011-06-21
SI2200980T1 (sl) 2011-12-30
KR101268654B1 (ko) 2013-05-29
KR20100069707A (ko) 2010-06-24
AU2008315309B2 (en) 2011-06-09
CA2703157A1 (en) 2009-04-30
JP2011500792A (ja) 2011-01-06
CA2703157C (en) 2013-02-05
IL205231A0 (en) 2010-12-30
AU2008315309A1 (en) 2009-04-30
IL205231A (en) 2014-03-31
ES2370680T9 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
TWI827646B (zh) Ptpn11抑制劑
US20240009153A1 (en) Bumetanide analogs, compositions and methods of use
EP3055299B1 (en) Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
WO2012018635A2 (en) Arylsulfonamide derivatives, compositions, and methods of use
TR201809293T4 (tr) Polisiklik LPA1 antagonisti ve kullanımları.
CA2895426A1 (en) Bet-protein-inhibiting dihydroquinoxalinones
HRP20110780T2 (hr) Aminoarilsulfonamidni spojevi i njihova upotreba kao ligandi 5-ht6
UA93872C2 (ru) Дигидротиенопиримидины для лечения воспалительных заболеваний
BR112020002348A2 (pt) derivados de quinolina para tratamento de infecções por helmintos.
AU2013271731A1 (en) SecA inhibitors and methods of making and using thereof
CA2992364A1 (en) 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
JP2009511629A (ja) 中枢神経系疾患の調節に有用な利尿薬様化合物類似体
WO2013059648A1 (en) 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use
CN102686575A (zh) G蛋白偶联受体88的调节剂
WO2016150971A1 (en) Aminoindazole derivatives as sodium channel inhibitors
JP2011231094A (ja) ブメタニド、フロセミド、ピレタニド、アゾセミド、およびトルセミドのアナログ、組成物および使用方法
AU2021398540A1 (en) Anthelmintic compounds comprising a pyridine structure
AU2016353348A1 (en) Heterocyclic compounds for the treatment of disease
CA2911156A1 (en) Neurogenesis-stimulating isoquinoline derivatives
PT2997027T (pt) Novos (ciano-dimetil-metil)-isoxazóis e -[1,3,4]tiadiazóis
EP2419411A1 (en) Quinoxaline derivatives and their use for treating benign and malignant tumour disorders
WO2015085860A1 (zh) 杂环羟肟酸类化合物及其药用组合物和应用
CA3182964A1 (en) 1,4,5,6-tetrahydropyrimidin-2-amine derivative
JP2022115836A (ja) Ｌｐａ１受容体を拮抗するウレア化合物を有効成分として含有する医薬
EP3650440A1 (en) Benzoic ester compound